FDA Reviews Safety of Abortion Drug Mifepristone

The FDA is moving forward with a safety review of the abortion pill mifepristone, a move that marks a victory for anti-abortion groups seeking stricter regulations. This review could significantly impact reproductive healthcare access and signals a shift in federal oversight of pharmaceutical safety. The decision carries broader implications for the ongoing culture war and election dynamics regarding life issues.